Related Experiment Video

Updated: May 14, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

[Lung cancer. Molecular pathology and personalized therapy]

A Schultheis1, J Wolf, R Büttner

  • 1Institut für Pathologie, CIO Köln Bonn, Universitätsklinikum Köln, Kerpener Str. 62, 50937, Köln. anne.schultheis@uk-koeln.de

Der Internist
|February 2, 2013
PubMed

Insights

Personalized non-small cell lung cancer (NSCLC) treatments target driver mutations. Understanding the complex interplay between lung cancer and the immune system, particularly immune checkpoints, is key for effective cancer immunotherapy and biomarker discovery.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Context:

  • Non-small cell lung cancer (NSCLC) treatment is increasingly personalized, focusing on specific genetic mutations.
  • Approximately 15% of NSCLC patients currently benefit from genotype-driven therapies.
  • Cancer immunotherapy, encompassing adaptive and innate immunity, has re-emerged as a significant therapeutic strategy.

Purpose:

  • To explore the role of driver mutations in personalizing NSCLC treatment.
  • To review current cancer immunotherapy approaches, including monoclonal antibodies, vaccines, cell transfer, and immune checkpoint blockade.
  • To emphasize the need for a deeper understanding of lung cancer-immune system interactions for personalized immunotherapy.

Summary:

  • Advances in NSCLC treatment leverage driver mutations for personalized medicine.
  • Cancer immunotherapy strategies include antibodies, vaccines, cell therapies, and immune checkpoint inhibitors.
  • Combining existing treatments with immunotherapy shows promise for enhanced antitumor effects.
  • Understanding immune checkpoints is crucial for developing personalized immunotherapy biomarkers.

Impact:

  • Improved treatment protocols for a subset of NSCLC patients based on tumor genetics.
  • Development of novel immunotherapeutic strategies for lung cancer.
  • Potential identification of biomarkers to guide personalized cancer immunotherapy decisions.
  • Enhanced antitumor efficacy through combination therapies targeting both cancer genetics and immune pathways.

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...